샘플 요청 목록

 카트 문의
시장보고서
상품코드
2052203

제네릭 항암제 시장 : 시장 인사이트, 경쟁 구도 및 시장 예측(2033년)

Generic Oncology Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033
발행일: | 리서치사: 구분자 Fairfield Market Research | 페이지 정보: 영문 199 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



가격
Unprintable PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.
US $ 4,995 금액 안내 화살표 ￦ 7,680,000
Unprintable PDF & Excel (Multi User License upto 5 users) help
PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.
US $ 8,495 금액 안내 화살표 ￦ 13,062,000
Printable PDF & Excel (Enterprise License above 5 users) help
PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,600 금액 안내 화살표 ￦ 16,299,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

의료진들이 합리적인 가격과 접근성이 높은 암 치료제에 대한 관심이 높아지면서 제네릭 항암제 시장은 전 세계적으로 큰 성장세를 보이고 있습니다. 암 환자 수 증가, 의료비 증가, 브랜드 항암제 특허 만료 등이 시장 확대를 뒷받침하는 주요 요인으로 작용하고 있습니다. 제네릭 항암제는 치료 효과를 유지하면서 비용 효율적인 치료 옵션을 제공하기 때문에 선진국과 신흥국 의료 시장 모두에서 높은 지지를 받고 있습니다. 세계 제네릭 항암제 시장 규모는 2026년 281억 달러로 평가되며, 2033년까지 434억 달러에 달할 것으로 예상됩니다. 예측 기간 동안 CAGR 6.40%로 성장할 것으로 예상됩니다.

암 조기 진단 및 치료에 대한 인식이 높아진 데다 정부의 제네릭 의약품 육성 지원책이 더해져 시장 성장이 더욱 가속화되고 있습니다. 제약사들은 또한 시장에서의 입지를 강화하고 전 세계적으로 증가하는 수요를 충족시키기 위해 항암제 제품 파이프라인을 확장하고 있습니다.

시장 인사이트

브랜드 암 치료제를 대체할 수 있는 저비용 대안이 등장하면서 시장은 꾸준히 성장하고 있습니다. 제네릭 항암제는 유방암, 폐암, 혈액암, 대장암 및 기타 여러 악성 종양 치료에 널리 사용되고 있습니다. 의료 시스템이 비용 최적화를 최우선 과제로 삼고 있는 가운데, 제네릭 의약품은 전 세계 암 치료 전략에서 필수적인 요소로 자리 잡고 있습니다.

경구용 항암제의 채택 확대는 환자의 편의성을 높이고 장기 입원에 대한 의존도를 낮춤으로써 치료의 제공 형태를 바꾸고 있습니다. 이와 함께 병원 약국 및 온라인 약국 플랫폼은 여러 지역에서 항암제 제네릭 의약품의 접근성을 높이고 있습니다.

제약사들은 끊임없이 변화하는 제약 산업에서 경쟁력을 유지하기 위해 생산 효율성 향상, 공급망 강화, 고품질 제제 도입에 주력하고 있습니다. 또한, 제네릭 의약품의 신속한 승인을 위한 규제적 측면의 지원도 시장 확대에 크게 기여하고 있습니다.

촉진요인

제네릭 항암제 시장을 이끄는 주요 요인은 전 세계적으로 암 유병률이 증가하고 있다는 점입니다. 고령화, 건강에 해로운 생활습관, 흡연 습관, 환경적 요인이 암 진단 건수 증가에 기여하고 있으며, 이에 따라 합리적인 가격의 치료 솔루션에 대한 수요가 증가하고 있습니다.

일부 브랜드 항암제의 특허 만료는 제네릭 제조사들에게 기회로 작용하고 있습니다. 특허가 만료됨에 따라 제약회사는 수요가 많은 암 치료제의 비용 효율적인 버전을 출시할 수 있게 되어 환자의 접근성을 높이고 전체 치료 비용을 절감할 수 있게 됩니다.

제네릭 의약품 사용을 장려하는 정부의 노력도 시장 성장을 뒷받침하고 있습니다. 많은 국가들이 의료비 절감과 필수적인 암 치료제에 대한 접근성 향상을 위한 정책을 시행하고 있습니다. 또한, 개발도상국의 의료 인프라 확충으로 암 치료 시설과 의약품에 대한 접근성이 개선되고 있습니다.

제약 제조 기술의 발전으로 기업들은 효능과 안전성이 향상된 고품질 제네릭 의약품을 생산할 수 있게 되었습니다. 바이오시밀러 항암제 개발이 진행되고 있어 향후 몇 년 동안 시장 기회는 더욱 확대될 것으로 예상됩니다.

비즈니스 기회

제네릭 항암제 시장은 제약사 및 이해관계자들에게 큰 성장 잠재력을 제공하고 있습니다. 신흥국 시장은 의료 투자 증가, 암에 대한 인식 증가, 의료 인프라 개선으로 인해 매우 수익성이 높은 시장으로 부상하고 있습니다.

각 업체들은 항암제 제품 포트폴리오를 확장하고 경쟁 우위를 확보하기 위해 연구개발 활동에 대한 투자를 점점 더 늘리고 있습니다. 바이오시밀러와 고분자 제네릭 의약품의 개발은 특히 표적항암제 및 바이오의약품 분야에서 새로운 비즈니스 기회를 창출할 것으로 예상됩니다.

디지털 헬스케어의 확대와 온라인 약국의 급속한 성장도 항암제 제조업체에게 새로운 유통 기회를 열어주고 있습니다. 온라인 약국 플랫폼은 원격지나 의료서비스가 부족한 지역의 환자들의 의약품 접근성을 개선하고, 시장 침투 확대에 기여하고 있습니다.

전략적 제휴, 파트너십 및 인수는 여전히 주요 기업의 중요한 성장 전략으로 자리 잡고 있습니다. 많은 기업들이 파트너십을 맺어 제조 능력을 강화하고, 유통망을 개선하고, 국제 시장에서 제품 상용화를 가속화하기 위해 파트너십을 맺고 있습니다.

지역별 분석

북미는 높은 암 발병률, 탄탄한 의료 인프라, 제네릭 의약품의 보급으로 제네릭 항암제 시장을 독점하고 있습니다. 또한, 이 지역은 유리한 상환 정책과 항암제 개발에 주력하는 대형 제약사의 존재로 인해 수혜를 받고 있습니다.

유럽은 의료비 억제책 강화와 제네릭 의약품 도입에 대한 강력한 규제적 지원에 힘입어 여전히 중요한 시장으로 자리매김하고 있습니다. 독일, 프랑스, 영국 등의 국가들은 공공 의료 시스템 내에서 제네릭 의약품의 사용을 지속적으로 장려하고 있습니다.

아시아태평양은 예측 기간 동안 가장 빠른 성장을 기록할 것으로 예상됩니다. 암 발병률 증가, 의료 인프라 확충, 인도와 중국 등의 국가에서의 제약 제조 활동 증가가 이 지역의 시장 확대를 견인하고 있습니다. 합리적인 가격의 암 치료 접근성을 개선하기 위한 정부의 노력도 성장을 뒷받침하고 있습니다.

라틴아메리카와 중동 및 아프리카에서도 의료 접근성 향상과 암 치료 옵션에 대한 인식이 높아짐에 따라 시장이 꾸준히 성장하고 있습니다. 의료 현대화를 위한 투자 증가는 이들 지역 전반에 걸쳐 더 많은 성장 기회를 창출할 것으로 예상됩니다.

주요 기업

  • Teva Pharmaceutical Industries Ltd.
  • Sandoz Group AG
  • Mylan N.V.(Viatris)
  • Biocon
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Lupin Pharmaceuticals
  • Zydus Cadila

세분화

분자별

  • 고분자
  • 저분자

투여 경로별

  • 경구
  • 비경구

판매 채널별

  • 소매 약국
  • 병원 약국
  • 온라인 약국

지역별

  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

목차

제1장 주요 요약

제2장 시장 개요

제3장 세계의 제네릭 항암제 시장 전망, 2020-2033년

제4장 북미의 제네릭 항암제 시장 전망, 2020-2033년

제5장 유럽의 제네릭 항암제 시장 전망, 2020-2033년

제6장 아시아태평양의 제네릭 항암제 시장 전망, 2020-2033년

제7장 라틴아메리카의 제네릭 항암제 시장 전망, 2020-2033년

제8장 중동 및 아프리카의 제네릭 항암제 시장 전망, 2020-2033년

제9장 경쟁 구도

제10장 부록

KSM

The Generic Oncology Drugs Market is gaining substantial momentum worldwide as healthcare providers increasingly focus on affordable and accessible cancer therapies. The growing burden of cancer cases, rising healthcare expenditures, and the expiration of patents for branded oncology drugs are major factors supporting market expansion. Generic oncology medications offer cost-effective treatment alternatives while maintaining therapeutic effectiveness, making them highly preferred across both developed and emerging healthcare markets. The global Generic Oncology Drugs Market is valued at US$ 28.1 Bn in 2026 and is projected to reach US$ 43.4 Bn by 2033, growing at a CAGR of 6.40% during the forecast period.

Increasing awareness regarding early cancer diagnosis and treatment, along with supportive government initiatives promoting generic medicines, is further accelerating market growth. Pharmaceutical manufacturers are also expanding their oncology product pipelines to strengthen market presence and meet rising global demand.

Market Insights

The market is experiencing consistent growth due to the increasing availability of low-cost alternatives to branded cancer therapies. Generic oncology drugs are extensively used in the treatment of breast cancer, lung cancer, blood cancer, colorectal cancer, and several other malignancies. As healthcare systems continue to prioritize cost optimization, generic medicines are becoming a vital component of cancer care strategies worldwide.

The growing adoption of oral oncology medications is reshaping treatment delivery by improving convenience for patients and reducing dependency on prolonged hospital stays. In parallel, hospital pharmacies and online pharmacy platforms are enhancing the accessibility of oncology generics across multiple regions.

Manufacturers are focusing on improving production efficiency, strengthening supply chains, and introducing high-quality formulations to remain competitive in the evolving pharmaceutical landscape. Regulatory support for faster approvals of generic medicines is also contributing significantly to market expansion.

Drivers

A major factor driving the Generic Oncology Drugs Market is the increasing prevalence of cancer globally. Aging populations, unhealthy lifestyles, smoking habits, and environmental factors are contributing to the rising number of cancer diagnoses, thereby increasing the demand for affordable treatment solutions.

Patent expirations of several branded oncology drugs are creating favorable opportunities for generic manufacturers. As patents expire, pharmaceutical companies can launch cost-effective versions of high-demand cancer therapies, enabling wider patient access and reducing overall treatment costs.

Government initiatives promoting the use of generic medicines are also supporting market growth. Many countries are implementing policies aimed at lowering healthcare spending and improving access to essential oncology drugs. In addition, expanding healthcare infrastructure in developing economies is enabling better access to cancer treatment facilities and pharmaceutical products.

Advancements in pharmaceutical manufacturing technologies are helping companies produce high-quality generic drugs with enhanced efficacy and safety standards. The increasing development of biosimilar oncology products is expected to further strengthen market opportunities in the coming years.

Business Opportunity

The Generic Oncology Drugs Market offers strong growth potential for pharmaceutical manufacturers and healthcare stakeholders. Emerging economies represent highly lucrative markets due to rising healthcare investments, growing cancer awareness, and improving medical infrastructure.

Companies are increasingly investing in research and development activities to expand their oncology drug portfolios and gain competitive advantages. The development of biosimilars and large molecule generics is expected to create new business opportunities, particularly in targeted cancer therapies and biologics.

Digital healthcare expansion and the rapid growth of online pharmacies are also opening new distribution opportunities for oncology drug manufacturers. E-pharmacy platforms are improving medication accessibility for patients in remote and underserved areas, contributing to broader market penetration.

Strategic collaborations, partnerships, and acquisitions remain important growth strategies among leading pharmaceutical companies. Many firms are entering partnerships to strengthen manufacturing capabilities, improve distribution networks, and accelerate product commercialization across international markets.

Region Analysis

North America dominates the Generic Oncology Drugs Market due to the high prevalence of cancer, strong healthcare infrastructure, and widespread adoption of generic medicines. The region also benefits from favorable reimbursement policies and the presence of major pharmaceutical companies focused on oncology drug development.

Europe remains a significant market supported by increasing healthcare cost containment measures and strong regulatory support for generic drug adoption. Countries including Germany, France, and the United Kingdom continue to encourage the use of generic medicines within public healthcare systems.

Asia Pacific is expected to register the fastest growth during the forecast period. Rising cancer incidence, expanding healthcare infrastructure, and increasing pharmaceutical manufacturing activities in countries such as India and China are driving regional market expansion. Government initiatives aimed at improving access to affordable cancer treatment are further supporting growth.

Latin America and the Middle East & Africa are also witnessing steady market development due to improving healthcare accessibility and rising awareness regarding cancer treatment options. Increasing investments in healthcare modernization are expected to create additional growth opportunities across these regions.

Key Players

  • Teva Pharmaceutical Industries Ltd.
  • Sandoz Group AG
  • Mylan N.V. (Viatris)
  • Biocon
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Lupin Pharmaceuticals
  • Zydus Cadila

Segmentation

By Molecule

  • Large Molecule
  • Small Molecule

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Generic Oncology Drugs Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 3.1. Global Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 3.1.1. Large Molecule
    • 3.1.2. Small Molecule
  • 3.2. Global Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 3.2.1. Oral
    • 3.2.2. Parenteral
  • 3.3. Global Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.3.1. Retail Pharmacies
    • 3.3.2. Hospital Pharmacies
    • 3.3.3. Online Pharmacies
  • 3.4. Global Generic Oncology Drugs Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 4.1. North America Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 4.1.1. Large Molecule
    • 4.1.2. Small Molecule
  • 4.2. North America Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 4.2.1. Oral
    • 4.2.2. Parenteral
  • 4.3. North America Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.3.1. Retail Pharmacies
    • 4.3.2. Hospital Pharmacies
    • 4.3.3. Online Pharmacies
  • 4.4. North America Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 4.4.2. U.S. Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 4.4.3. U.S. Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 4.4.4. Canada Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 4.4.5. Canada Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 4.4.6. Canada Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 5.1. Europe Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 5.1.1. Large Molecule
    • 5.1.2. Small Molecule
  • 5.2. Europe Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Europe Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.3.1. Retail Pharmacies
    • 5.3.2. Hospital Pharmacies
    • 5.3.3. Online Pharmacies
  • 5.4. Europe Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.2. Germany Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.3. Germany Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.4. Italy Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.5. Italy Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.6. Italy Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.7. France Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.8. France Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.9. France Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.10. U.K. Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.11. U.K. Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.12. U.K. Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.13. Spain Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.14. Spain Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.15. Spain Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.16. Russia Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.17. Russia Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.18. Russia Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.19. Rest of Europe Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 5.4.20. Rest of Europe Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.21. Rest of Europe Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 6.1.1. Large Molecule
    • 6.1.2. Small Molecule
  • 6.2. Asia Pacific Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Asia Pacific Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.3.1. Retail Pharmacies
    • 6.3.2. Hospital Pharmacies
    • 6.3.3. Online Pharmacies
  • 6.4. Asia Pacific Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.2. China Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.3. China Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.4. Japan Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.5. Japan Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.6. Japan Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.7. South Korea Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.8. South Korea Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.9. South Korea Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.10. India Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.11. India Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.12. India Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.13. Southeast Asia Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.14. Southeast Asia Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.15. Southeast Asia Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.16. Rest of SAO Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 6.4.17. Rest of SAO Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.18. Rest of SAO Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 7.1. Latin America Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 7.1.1. Large Molecule
    • 7.1.2. Small Molecule
  • 7.2. Latin America Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Latin America Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.3.1. Retail Pharmacies
    • 7.3.2. Hospital Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Latin America Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 7.4.2. Brazil Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.3. Brazil Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.4. Mexico Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 7.4.5. Mexico Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.6. Mexico Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.7. Argentina Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 7.4.8. Argentina Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.9. Argentina Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.10. Rest of LATAM Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 7.4.11. Rest of LATAM Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.12. Rest of LATAM Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Generic Oncology Drugs Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Generic Oncology Drugs Market Outlook, by Molecule, Value (US$ Bn), 2020-2033
    • 8.1.1. Large Molecule
    • 8.1.2. Small Molecule
  • 8.2. Middle East & Africa Generic Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Middle East & Africa Generic Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.3.1. Retail Pharmacies
    • 8.3.2. Hospital Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Middle East & Africa Generic Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 8.4.2. GCC Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.3. GCC Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.4. South Africa Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 8.4.5. South Africa Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.6. South Africa Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.7. Egypt Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 8.4.8. Egypt Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.9. Egypt Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.10. Nigeria Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 8.4.11. Nigeria Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.12. Nigeria Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.13. Rest of Middle East Generic Oncology Drugs Market Outlook, by Molecule, 2020-2033
    • 8.4.14. Rest of Middle East Generic Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.15. Rest of Middle East Generic Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Teva Pharmaceutical Industries Ltd.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Sandoz Group AG
    • 9.4.3. Mylan N.V. (Viatris)
    • 9.4.4. Biocon
    • 9.4.5. Sun Pharmaceutical Industries Ltd.
    • 9.4.6. Lupin Pharmaceuticals
    • 9.4.7. Fresenius Kabi AG
    • 9.4.8. Pfizer Inc.
    • 9.4.9. Lupin Pharmaceuticals
    • 9.4.10. Zydus Cadila

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기